Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1 -Mutated or KMT2A -Rearranged AML
Journal of Clinical Oncology · 10.08.2025 · 43 (23) · 2606-2615
DOI: 10.1200/jco-25-00914 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.08.2025. Verfasst von Joshua F Zeidner und 32 weiteren Autor:innen. Beteiligte Einrichtung: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols, Histone-Lysine N-Methyltransferase, Mutation. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Azacitidine and venetoclax is a standard frontline treatment regimen for newly diagnosed older adults with AML; however, long-term outcomes remain poor. Revumenib is an oral menin inhibitor with clinical activity in AML patients with nucleophosmin-1 mutation ( NPM1m ) or lysine methyltransferase 2A rearrangements ( KMT2Ar ). METHODS We conducted a phase I dose-escalation and expansion study of azacitidine, venetoclax, and revumenib at two dose levels (113 mg or 163 mg orally every 12 hours in combination with strong cytochrome P450 inhibitor azoles) in patients aged 60 years and older newly diagnosed with AML with NPM1m or KMT2Ar (ClinicalTrials.gov identifier: NCT03013998 ). RESULTS Overall, 43 patients were enrolled and treated. There was no maximal tolerated dose identified. Differentiation syndrome was present in eight (19%) patients and QTc Fridericia prolongation was present in 19 (44%) patients, and neither required permanent discontinuation of revumenib. The overall response rate with an intention-to-treat population was 88.4% (95% CI, 74.9 to 96.1; NPM1m : 85.3%; KMT2Ar : 100%), the rate of composite complete remission (complete remission [CR] + CR with partial or incomplete hematologic recovery) was 81.4% (95% CI, 66.6 to 91.6; NPM1m: 79.4%; KMT2Ar: 88.9%), and the rate of CR was 67.4% (95% CI, 51.5 to 80.9; NPM1m : 65%; KMT2Ar : 78%). No patient had refractory disease after 1-2 cycles of treatment. The median time to first response was 28 days, and 84% of responders achieved remission within the first cycle. All 37 patients evaluated had no evidence of measurable residual disease by a centralized flow cytometry assay. CONCLUSION In older adults newly diagnosed with NPM1m or KMT2Ar AML, the combination of azacitidine, venetoclax, and revumenib was able to be safely administered with high rates of CR and clinical activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.
- University of Kansas Medical Center, Kansas City, KS.
- The Ohio State University, Columbus, OH.
- University of Cincinnati, Cincinnati, OH.
- University of Chicago Comprehensive Cancer Center, Chicago, IL.
- University of Texas Southwestern Medical Center, Dallas, TX.
ORCID-Profile: Joshua F Zeidner, Rina Li Welkie, Wendy Stock, William Blum, Eytan M Stein, Rebecca L Olin, Elie Traer, Curtis Lachowiez, Michael J Hochman, Sheng F Cai, Catherine Smith, Mona Stefanos, Timothy L Chen, Ashley O Yocum, Brian J Druker, Uma Borate, John C Byrd, Alice S Mims
Förderung
- NCI NIH HHS
Zitieren
APA
Zeidner, J. F., Lin, T. L., Welkie, R. L., Curran, E., Koenig, K., Stock, W., Madanat, Y. F., Swords, R., Baer, M. R., Blum, W., Stein, E. M., Olin, R. L., Schiller, G., Nichols, A., Odenike, O., Traer, E., Lachowiez, C., Duong, V. H., Hochman, M. J., …, & Mims, A. S. (2025). Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1 -Mutated or KMT2A -Rearranged AML. Journal of Clinical Oncology, 43(23), 2606-2615. https://doi.org/10.1200/jco-25-00914
Vancouver
Zeidner JF, Lin TL, Welkie RL, Curran E, Koenig K, Stock W, et al. Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1 -Mutated or KMT2A -Rearranged AML. Journal of Clinical Oncology. 2025;43(23):2606-2615. doi:10.1200/jco-25-00914
BibTeX
@article{Zeidner2025,
author = {Zeidner, Joshua F and Lin, Tara L and Welkie, Rina Li and Curran, Emily and Koenig, Kristin and Stock, Wendy and Madanat, Yazan F and Swords, Ronan and Baer, Maria R and Blum, William and Stein, Eytan M and Olin, Rebecca L and Schiller, Gary and Nichols, Angela and Odenike, Olatoyosi and Traer, Elie and Lachowiez, Curtis and Duong, Vu H and Hochman, Michael J and Cai, Sheng F and Smith, Catherine and Stefanos, Mona and Martycz, Molly and Huang, Ying and Rosenberg, Len and Marcus, Sonja and Chen, Timothy L and Yocum, Ashley O and Druker, Brian J and Levine, Ross L and Borate, Uma and Byrd, John C and Mims, Alice S},
title = {Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1 -Mutated or KMT2A -Rearranged AML},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {23},
pages = {2606--2615},
doi = {10.1200/jco-25-00914}
}
EUVIMED